Prevalence of driver mutations in non-small-cell lung cancers in the People's Republic of China [0.03%]
中国非小细胞肺癌驱动基因的流行病学研究
Lan-Ying Gou,Yi-Long Wu
Lan-Ying Gou
Lung cancer is a leading cause of cancer-related mortality worldwide and in the People's Republic of China. Recently, the pathological proportions of the various forms of lung cancer have changed. A shift to a preponderance of adenocarcinom...
Potential toxicity and safety evaluation of nanomaterials for the respiratory system and lung cancer [0.03%]
纳米材料的潜在毒性和安全性评价及其对呼吸系统和肺癌的影响
Thomais Vlachogianni,Konstantinos Fiotakis,Spyridon Loridas et al.
Thomais Vlachogianni et al.
Engineered nanomaterials (ENMs) are a diverse group of materials finding increasing use in manufacturing, computing, food, pharmaceuticals, and biomedicine due to their very small size and exceptional properties. Health and safety concerns ...
Practical management of NSCLC patients with long-term bevacizumab treatment: a report of four cases [0.03%]
贝伐珠单抗长期治疗非小细胞肺癌患者的管理体会-四例报告及文献复习
Gjm Herder,H Codrington,C D Colder et al.
Gjm Herder et al.
Introduction: Previous research showed that the addition of bevacizumab (a monoclonal antibody against vascular endothelial growth factor [VEGF]) to chemotherapy resulted in a significant efficacy benefit in the treatment...
Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond [0.03%]
肺癌的个体化治疗研究——EGFR突变及其他
Kenichi Suda,Tetsuya Mitsudomi
Kenichi Suda
Lung cancers with epidermal growth factor receptor (EGFR) gene mutation account for ∼40% of adenocarcinoma in East Asians and ∼15% of that in Caucasians, which makes them one of the most common molecularly defined lung cancer subsets. The...
Robotic stereotactic body radiation therapy for elderly medically inoperable early-stage non-small cell lung cancer [0.03%]
老年医学上不可手术的早期非小细胞肺癌的立体定向体部放射治疗
Sana D Karam,Zachary D Horne,Robert L Hong et al.
Sana D Karam et al.
Introduction: Stereotactic body radiation therapy (SBRT) is being increasingly applied in the treatment of non-small cell lung cancer (NSCLC) because of its high local efficacy. This study aims to examine survival outcome...
EGFR mutations in patients with lung adenocarcinoma in southwest China: are G719S/A and L861Q more likely detected in tumors derived from smokers? [0.03%]
中国西南部肺腺癌患者中的表皮生长因子受体突变：G719S/A和L861Q突变更有可能出现在吸烟者来源的肿瘤中吗？
Qiushi Wang,Jianghong Mou,Xin Yang et al.
Qiushi Wang et al.
Background: The clinical characteristics of epidermal growth factor receptor (EGFR) hotspot mutations, such as deletions in exon 19, substitution of L858R in exon 21, and mutations in exon 20, have been widely reported in...
MET overexpression and gene amplification in NSCLC: a clinical perspective [0.03%]
NSCLC中MET过表达和基因扩增的临床意义
Lorenza Landi,Gabriele Minuti,Armida D&#x;Incecco et al.
Lorenza Landi et al.
The transmembrane tyrosine kinase mesenchymal-epidermal transition (MET) receptor and its ligand, hepatocyte growth factor, also known as scatter factor, have recently been identified as novel promising targets in several human malignancies...
Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy [0.03%]
吉非替尼可致既往接受过化疗的肺腺癌患者频繁发生肝损害
Yasoo Sugiura,Etsuo Nemoto,Osamu Kawai et al.
Yasoo Sugiura et al.
Background: Gefitinib is known as one of the agents for treating patients with both advanced lung cancer and an epidermal growth-factor receptor mutation. In the epidermal growth-factor receptor-mutant advanced non-small-...
Eunice L Kwak,Jeffrey W Clark,Alice T Shaw
Eunice L Kwak
The oncogenic function of gene translocations involving the anaplastic lymphoma kinase (ALK) was first reported in rare subtypes of non-Hodgkin's lymphoma almost two decades ago. More recently, aberrant ALK signaling was found to be an onco...
Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer [0.03%]
第二代表皮生长因子受体酪氨酸激酶抑制剂治疗非小细胞肺癌患者的疗效和安全性系统评价及meta分析
Thierry Berghmans,Myriam Remmelink,Ahmad Awada
Thierry Berghmans
Targeted therapies are nowadays a treatment option in metastatic non-small cell lung cancer, for which oncogenic drivers have been identified. The epidermal growth factor-receptor tyrosine kinase inhibitors gefitinib and erlotinib, are the ...